En vivo
Merck KGaAMerck KGaA Backs Hybrid Cancer Drugs And Greener Lab Consumables - simplywall.stBioPharma DiveArvinas’ ‘Protac’ breast cancer drug cleared by FDAEndpoints NewsModerna in talks with FDA over Phase 4 Covid vaccine dataBio-RadBio-Rad Weighs 2026 Outlook As Middle East Headwinds Meet Stilla Hopes - simplywall.stEndpoints NewsFDA approves Pfizer and Arvinas' breast cancer drug despite underwhelming dataModernaModerna’s first quarter 2026 sales well ahead of estimates - The Pharma LetterEndpoints NewsAmgen launches late-stage obesity trial in patients who switch from rival drugsFierceBiotech‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPOCytiva (Google News)Figurate SCADA System Launched to Overcome Digital Bottlenecks During Biopharma Manufacturing - Genetic Engineering and Biotechnology NewsBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-April 30, 2026Endpoints NewsQ&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research
Merck KGaA 1 may 2026

Merck KGaA Backs Hybrid Cancer Drugs And Greener Lab Consumables - simplywall.st

Merck KGaA Backs Hybrid Cancer Drugs And Greener Lab Consumables - simplywall.st

Original
Contenido no disponible. Consulta la fuente original.